Axon Enterprise (NASDAQ:AXON – Get Rating) had its target price cut by stock analysts at Credit Suisse Group from $169.00 to $134.00 in a research note issued on Thursday, The Fly reports. Credit Suisse Group's price target would indicate a potential upside of 41.57% from the stock's previous close.
Several other equities analysts have also weighed in on AXON. Northland Securities reduced their price objective on shares of Axon Enterprise from $180.00 to $130.00 in a research report on Thursday, May 12th. Robert W. Baird reduced their price objective on shares of Axon Enterprise from $145.00 to $125.00 in a research report on Wednesday, May 11th. StockNews.com raised shares of Axon Enterprise from a "hold" rating to a "buy" rating in a research note on Saturday, June 18th. Morgan Stanley lowered shares of Axon Enterprise from an "overweight" rating to an "equal weight" rating and set a $120.00 price objective for the company. in a research note on Monday, May 23rd. Finally, JMP Securities reaffirmed a "buy" rating and set a $195.00 price objective on shares of Axon Enterprise in a research note on Wednesday, June 1st. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Axon Enterprise has an average rating of "Buy" and a consensus price target of $169.00.
Get Axon Enterprise alerts:Axon Enterprise Stock Performance
Shares of AXON opened at $94.65 on Thursday. Axon Enterprise has a 52-week low of $82.49 and a 52-week high of $209.00. The company has a quick ratio of 2.18, a current ratio of 2.43 and a debt-to-equity ratio of 0.02. The firm has a 50-day moving average price of $94.58 and a 200 day moving average price of $116.57. The firm has a market capitalization of $6.72 billion, a PE ratio of 182.02 and a beta of 0.61.
Axon Enterprise (NASDAQ:AXON – Get Rating) last posted its quarterly earnings data on Tuesday, May 10th. The biotechnology company reported $0.76 earnings per share for the quarter. Axon Enterprise had a net margin of 4.62% and a return on equity of 3.90%. The company had revenue of $256.43 million during the quarter, compared to analyst estimates of $233.57 million. During the same quarter last year, the firm posted ($0.75) EPS. The business's revenue for the quarter was up 31.5% on a year-over-year basis. On average, sell-side analysts anticipate that Axon Enterprise will post 1.35 earnings per share for the current fiscal year.Insider Transactions at Axon Enterprise
In other news, Director Mark W. Kroll sold 3,159 shares of the stock in a transaction that occurred on Wednesday, June 8th. The shares were sold at an average price of $102.82, for a total value of $324,808.38. Following the completion of the sale, the director now directly owns 13,691 shares of the company's stock, valued at $1,407,708.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 6.90% of the stock is owned by insiders.
Institutional Trading of Axon Enterprise
A number of hedge funds have recently made changes to their positions in the stock. Nisa Investment Advisors LLC lifted its position in shares of Axon Enterprise by 25.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 495 shares of the biotechnology company's stock worth $69,000 after purchasing an additional 100 shares in the last quarter. Advisor Group Holdings Inc. raised its position in Axon Enterprise by 0.6% during the fourth quarter. Advisor Group Holdings Inc. now owns 17,989 shares of the biotechnology company's stock valued at $2,823,000 after acquiring an additional 100 shares in the last quarter. GM Advisory Group Inc. raised its position in Axon Enterprise by 3.2% during the fourth quarter. GM Advisory Group Inc. now owns 3,266 shares of the biotechnology company's stock valued at $513,000 after acquiring an additional 101 shares in the last quarter. State of Alaska Department of Revenue raised its position in Axon Enterprise by 1.3% during the first quarter. State of Alaska Department of Revenue now owns 9,636 shares of the biotechnology company's stock valued at $1,327,000 after acquiring an additional 120 shares in the last quarter. Finally, Stratos Wealth Partners LTD. raised its position in Axon Enterprise by 2.8% during the first quarter. Stratos Wealth Partners LTD. now owns 4,663 shares of the biotechnology company's stock valued at $642,000 after acquiring an additional 125 shares in the last quarter. 72.06% of the stock is owned by hedge funds and other institutional investors.
Axon Enterprise Company Profile
(Get Rating)
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, TASER, and Software and Sensors. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
See Also
- Get a free copy of the StockNews.com research report on Axon Enterprise (AXON)
- MarketBeat: Week in Review 7/11 – 7/15
- Is Coupang's Stock On The Verge Of A Turnaround?
- Should You Have These Two Banks In Your Portfolio?
- Verint Systems Stock is a Customer Engagement Play
- Why Shopify Stock Split...And is as Shoppable as Ever
Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.